Biologicals in gastroenterology: TNF-blockers

被引：1
|
作者：
Scharl, M. [1 ]
Rogler, G. [1 ]
机构：
[1] Univ Spital Zurich, Dept Innere Med, Klin Gastroenterol & Hepatol, CH-8091 Zurich, Switzerland
来源：
DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT | 2010年 / 135卷 / 45期
关键词：
inflammatory bowel disease; Crohn's disease; ulcerative colitis; TNF-blocker; biologicals; CROHNS-DISEASE; INFLIXIMAB MAINTENANCE; EPISODIC TREATMENT; ADALIMUMAB; THERAPY; EFFICACY; SAFETY; INFECTIONS; ANTIBODY;
D O I：
10.1055/s-0030-1267508
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
TNF-blockers represent a well accepted therapeutic option in the treatment of inflammatory bowel disease. Though they are successfully used in many patients, they can also exert severe side effects, such as infectious diseases. Therefore, a careful review of the patient history as well as a continuous evaluation of the patients state of health is crucial before starting an anti-TNF therapy during the therapeutic treatment. In addition, we review also the possibilities by loss of efficacy of an anti-TNF therapy, such as dose increase or re-induction therapy. © 2010 Georg Thieme Verlag KG Stuttgart · New York.
引用
下载
收藏
页码：2243 / 2252
页数：10
相关论文
共 50 条
  • [21] META-ANALYSIS COMPARING THE EFFICACY OF TNF-BLOCKERS IN AS AND NR-AXSPA PATIENTS
    Callhoff, J.
    Sieper, J.
    Weiss, A.
    Zink, A.
    Listing, J.
    ANNALS OF THE RHEUMATIC DISEASES, 2014, 73 : 721 - 721
  • [22] Low incidence of first cardiovascular event in rheumatoid arthritis patients treated with TNF-blockers
    Jacobsson, LTH
    Turesson, C
    Gülfe, A
    Crnkic, M
    Petersson, IF
    Saxne, T
    Geborek, P
    ARTHRITIS AND RHEUMATISM, 2003, 48 (09): : S241 - S241
  • [23] TNF-blockers are not associated with an increased overall tumor risk in rheumatoid arthritis patients.
    Geborek, P
    Bladström, A
    Turesson, C
    Gülfe, A
    Crnkic, M
    Petersson, IF
    Saxne, T
    Olsson, H
    Jacobsson, LTH
    ARTHRITIS AND RHEUMATISM, 2003, 48 (12): : 3652 - 3653
  • [24] TocilizumabWas kommt nach TNF-Blockern im klinischen AlltagTocilizumabWhat comes after TNF-blockers in clinical routine
    P. Roll
    A. Rubbert-Roth
    H.-P. Tony
    Zeitschrift für Rheumatologie, 2010, 69 : 608 - 617
  • [25] HOW CAN TNF-BLOCKERS BE STOPPED WITHOUT FLARE? NEEDS EARLY TREATMENT AND IMMUNOLOGICAL REMISSION
    Saleem, Benazir
    Parmar, Rekha
    Goeb, Vincent
    Conaghan, Philip G.
    Ponchel, Frederique
    Emery, Paul
    RHEUMATOLOGY, 2009, 48 : I136 - I137
  • [26] How should we be defining a meaningful clinical response to TNF-blockers in ankylosing spondylitis patients?
    Stone, M.
    Cortinovis, D.
    Raj, A. Govinda
    Maetzel, A.
    Inman, R.
    Lapp, V.
    Beaton, D.
    ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 544 - 544
  • [27] Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it
    Marcela Padilla-Martinez, Erika
    Romero-Sanchez, Consuelo
    Manuel Bello-Gualtero, Juan
    Maria Mesa-Betancourt, Ana
    Bautista-Molano, Wilson
    Valle-O, Rafael
    CURRENT RHEUMATOLOGY REVIEWS, 2019, 15 (04) : 329 - 335
  • [28] Familial Mediterranean fever (FMF)-response to TNF-blockers used for treatment of FMF patients with concurrent inflammatory diseases
    Haj-Yahia, Soad
    Ben-Zvi, Ilan
    Lidar, Merav
    Livneh, Avi
    JOINT BONE SPINE, 2021, 88 (05)
  • [29] How many ankylosing spondylitis patients consulting private practice rheumatologists are candidates to TNF-blockers? The AS prisme survey
    Pham, T
    Flipo, R
    Saraux, A
    ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 : 332 - +
  • [30] NO CLINICALLY RELEVANT CHANGES IN COAGULATION ACTIVATION BETWEEN PATIENTS INITIATING TNF-BLOCKERS VERSUS JAK-INHIBITORS
    Hansildaar, R.
    Raadsen, R.
    Heslinga, M.
    Nurmohamed, M. T.
    ANNALS OF THE RHEUMATIC DISEASES, 2023, 82 : 1382 - 1382
12345